Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Monday that it has entered into a clinical trial collaboration with biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) to evaluate ivonescimab in combination with GSK's investigational B7-H3 antibody drug conjugate, risvutatug rezetecan, across multiple solid tumour settings, including small cell lung cancer.
Ivonescimab is a novel, investigational PD-1 / VEGF bispecific antibody.
The collaboration with GSK aims to assess the safety profile and potential anti-tumour activity of the combination therapy.
Under the agreement, Summit will supply ivonescimab, while GSK will oversee day-to-day clinical trial operations. Each company will retain rights to its respective product, and the collaboration is structured as non-exclusive.
Clinical trials are expected to begin dosing patients in mid-2026.
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
GSK agrees US pricing framework to expand access to respiratory medicines
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
bioMérieux launches equine endocrinology tests to expand point-of-care diagnostics
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio